Latest News and Press Releases

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement”...

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today...

加州福斯特城, Oct. 17, 2025 (GLOBE NEWSWIRE) -- 總部設於加州的 Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「公司」) 是一家晚期臨床生物製藥公司，開發多種腫瘤候選藥物對抗難以根治及對治療有抗藥性的癌症。該公司較早時宣佈已向 The Nasdaq Stock Market, LLC (簡稱「Nasdaq」)...

加利福尼亚州福斯特城, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq 代码：APLM，以下简称 “Apollomics” 或“公司”) 是一家总部位于加利福尼亚州的晚期临床阶段生物制药公司，致力于开发多种针对难治性和耐药性癌症的候选肿瘤药物。此前，该公司曾宣布已提交申请，拟就 Nasdaq Stock Market, LLC...

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing...

加州福特斯城, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「該公司」) 今日發佈了以下公司營運的最新消息。 Apollomics 是一家臨床階段生物科技公司，致力推進創新腫瘤療法，為療選擇不多或別無選擇的患者改變治療格局。該公司的產品線擁有九種候選產品，涵蓋 11...

加州福特斯城, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq：APLM) (简称“Apollomics”或“公司”) 今日发布以下公司运营更新。 Apollomics 是一家临床阶段的生物技术公司，致力于推进创新肿瘤疗法，以改变那些治疗选择稀少或毫无选择的患者的治疗格局。公司目前在 11 个项目中拥有 9...

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a...

Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination...

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of...